The Global Cell and Gene Therapy Bio-Manufacturing Market Size is valued at USD 12.58 billion in 2023 and is predicted to reach USD 29.45 billion by the year 2031 at a 11.32% CAGR during the forecast period for 2024-2031.
The global cell and gene therapy bio-manufacturing market is advancing. The cell and gene therapy industry is rapidly expanding due to its promise to cure chronic and rare/orphan diseases that previously had few therapeutic choices. The development of sophisticated medicines has been critical in redefining the treatment paradigm of various life-threatening and uncommon diseases, as well as in reshaping the biopharmaceutical sector. The rapid expansion of the advanced therapy landscape is a key driver of the cell and gene therapy manufacturing market.
However, due to its unprecedented scale and severity, the COVID-19 epidemic has significantly disrupted social, economic, and political activities all around the world. As a result, COVID-19 has upset the cell and gene therapy (CGT) sector, which has historically suffered from considerable complexity in the supply of materials, production, and logistical operations.
Competitive Landscape:
Some of the Cell and Gene Therapy Bio-manufacturing Market players are:
- Becton, Dickinson and Company
- Endress+Hauser Group Services AG (Analytik Jena GmbH)
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- General Electric Company (G.E. Healthcare)
- Getinge AB
- Infors AG
- Lonza Group Ltd
- Merck KGaA
- Miltenyi Biotec B.V. & Co. KG
- PIERRE GUERIN
- Sartorius AG (Sartorius Stedim Biotech S.A.)
- Thermo Fisher Scientific Inc.
- WuXi AppTec
Market Segmentation:
The cell and gene therapy bio-manufacturing market is segmented on the basis of product type, usage, application, and end-user. Based on product type, the market is categorized as consumables, equipment, and software solutions. The usage segment includes commercial-stage manufacturing and research-stage manufacturing. By application, the market is segmented into upstream processing, harvesting, and downstream processing. The end-user segment includes life science companies, contract research organizations (CROs), contract manufacturing organizations (CMOs), and cell banks.
The Commercial Stage Manufacturing Segment Led The Cell And Gene Therapy Bio-Manufacturing Market Based On Usage
The commercial stage manufacturing segment category is expected to hold a considerable share in the global cell and gene therapy bio-manufacturing Market in 2024. As the number of regulatory approvals for gene and cell therapy products grows, so does the demand for commercial production of these medicines. To meet shifting industry demands, key market players such as Thermo Fisher Scientific and AGC Biologics are launching a number of strategic initiatives. For example, Thermo Fisher Scientific will launch new Patheon Commercial Packaging Services for cell and gene therapy in the United States and Europe in February 2022. This comprehensive solution integrates logistics, serialization compliance, and global distribution. Such characteristics are predicted to provide a favorable environment for segment expansion.
Contract Manufacturing Organizations Witness Growth At A Rapid Rate
The contract manufacturing organizations segment is projected to grow at a rapid rate in the global cell and gene therapy bio-manufacturing market. With rising demand for cell and gene therapies, a need for manufacturing capacity is opening up new prospects for contract manufacturing service providers. Due to the non-standardized and frequently changing nature of the cell and gene therapy sector, outsourcing to a contract manufacturing service provider is likely to provide a competitive advantage in terms of experience and competence.
The North America Cell And Gene Therapy Bio-Manufacturing Market In The Region Holds A Significant Revenue Share
The North America Cell and Gene Therapy Bio-manufacturing Market is expected to register the highest market share in terms of revenue in the near future. This can be attributed to the region's rising involvement in gene and cell therapy research and product development, as well as a large number of contract development businesses. Also, domestic firms are increasing their production operations in the region. Asia Pacific is expected to be a rising market for the production of cell and gene therapies. Cell treatment has gained traction in Asia during the last few years. This is due to the introduction of expedited approval procedures, increased healthcare requirements, and increased commercial and government spending.
Recent Developments:
- In January 2022, AllogeneTherapeutics Inc and AntionBiosciences Inc. formed an exclusive collaboration and global license agreement for Antion's miRNA technology (miCAR) to advance multiplex gene silencing as an additional tool in the development of next-generation allogeneic CAR T products.
Cell and Gene Therapy Bio-Manufacturing Market Report Scope:
|
Report Attribute |
Specifications |
|
Market size value in 2023 |
USD 12.58 Bn |
|
Revenue forecast in 2031 |
USD 29.45 Bn |
|
Growth rate CAGR |
CAGR of 11.32% from 2024 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Billion, and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Product Type, Usage, Application, And End-User |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Danaher Corporation, Endress+Hauser Group Services AG (Analytik Jena GmbH), General Electric Company (G.E. Healthcare), Getinge AB, Infors AG, Lonza Group Ltd, Merck KGaA, Miltenyi Biotec B.V. & Co. K.G., PIERRE GUERIN, Sartorius AG (Sartorius Stedim Biotech S.A.), Thermo Fisher Scientific Inc., and WuXi AppTec. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
